BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Up 68.0% in January

BrainsWay Ltd. (NASDAQ:BWAY - Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 63,000 shares, a growth of 68.0% from the January 15th total of 37,500 shares. Based on an average daily trading volume, of 67,300 shares, the days-to-cover ratio is currently 0.9 days.

Hedge Funds Weigh In On BrainsWay

Institutional investors and hedge funds have recently modified their holdings of the business. Valor Management LLC bought a new position in BrainsWay in the fourth quarter valued at approximately $19,838,000. Phoenix Financial Ltd. raised its holdings in shares of BrainsWay by 100.8% during the fourth quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company's stock worth $4,552,000 after acquiring an additional 242,366 shares during the period. ARK Investment Management LLC bought a new stake in BrainsWay in the 4th quarter valued at $1,656,000. MYDA Advisors LLC lifted its position in BrainsWay by 100.2% in the 4th quarter. MYDA Advisors LLC now owns 120,100 shares of the company's stock valued at $1,133,000 after acquiring an additional 60,100 shares in the last quarter. Finally, Zuckerman Investment Group LLC boosted its stake in BrainsWay by 346.4% in the 4th quarter. Zuckerman Investment Group LLC now owns 67,000 shares of the company's stock worth $667,000 after purchasing an additional 51,991 shares during the period. 30.11% of the stock is currently owned by institutional investors and hedge funds.

BrainsWay Stock Performance

BWAY stock traded up $0.28 during midday trading on Monday, hitting $11.30. 109,144 shares of the company's stock were exchanged, compared to its average volume of 56,067. BrainsWay has a one year low of $4.61 and a one year high of $11.50. The stock's fifty day moving average price is $10.04 and its 200-day moving average price is $9.29. The company has a market cap of $212.67 million, a PE ratio of 113.01 and a beta of 1.25.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of BrainsWay in a report on Monday, December 23rd.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.